FOR IMMEDIATE RELEASE
LYON, FRANCE, June 16, 2003 - Amgen (Nasdaq:AMGN), the world´s largest biotechnology company, presented data showing that three times as many anemic patients with lymphoid cancers receiving Aranesp?? (darbepoetin alfa) experienced increases in hemoglobin levels compared to those receiving placebo. These data support the recent recommendation by the European Committee on Proprietary Medicinal Products (CPMP) to extend the Aranesp?? label to include treatment of chemotherapy-induced anemia in adult patients with non-myeloid malignancies. Results from the study were presented at the European Hematology Association meeting by Michael Hedenus, MD, of Sundsvall Hospital, Sundsvall, Sweden.